Back to results
US 2003/0170215 A1Published application
In situ maturation of cultured pancreatic stem cells having a specified, intermediate stage of development
AssigneeAmCyte, Inc.
InventorsWen-Ghih Tsang, Tianli Zheng, Yanping Wang
Life of this patent
Estimating the term…
Abstract
This invention relates to the discovery that an intermediate, differentiated stage of pancreatic stem cells exist that can be matured in situ into a stable cell line that produces insulin in response to glucose. These cells are advantageous in that they are both expandable and stable in culture. This invention avoids the step of culturing the intermediate stage stem cells into later stage pancreatic cells.
Claims7
A in situ method of providing insulin to a mammal comprising the steps of:
- (a) encapsulating a cell culture of propagating pancreatic cells having the following properties:
- (i) the ability to be passed from one culture vessel to a second vessel at an initial concentration of about 180 cells per square centimeter and expanded to about 1,800 cells per square centimeter, and (ii) both the unexpanded and expanded cells are 90% PDX-1 positive and have an insulin:actin mRNA ratio of between 1:100 and 1000:1;
- (b) inserting the encapsulated cells into the mammal permitting the cells to mature to insulin secreting cells.
A composition comprising encapsulated pancreatic cells having the following properties:
- (i) the ability to be passed from one culture vessel to a second vessel at an initial concentration of about 180 cells per square centimeter and expanded to about 1,800 cells per square centimeter, and (ii) both the unexpanded and expanded cells are 90% PDX-1 positive and have an insulin:actin mRNA ratio of between 1:100 and 1000:1.
Dependencies are inferred from the claim text.